Total
0
Shares
NeuroScientific Biopharmaceuticals (ASX:NSB) - Managing Director & CEO, Matthew Liddelow
Managing Director & CEO, Matthew Liddelow
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation
  • Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs
  • EmtinB is currently being developed as a treatment for Alzheimer’s disease
  • NSB remains steady on the market today, trading for 18¢ per share

Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation.

Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs.

NSB expects this to begin in the second half of 2020.

EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease.

CEO and Managing Director Matt Liddelow is pleased with the agreement.

“NSB is excited to be working with PeptiStar and its globally recognized parent company, Mitsubishi,” he said.

“These companies will add significant peptide manufacturing expertise to NSB’s clinical development programs and we hope this agreement will be the first step towards a long-term manufacturing partnership with Mitsubishi and PeptiStar,” he added.

Recently, NSB announced significant positive results in a novel treatment for Multiple Sclerosis.

NSB remains steady on the market today, trading for 18¢ per share at 1:37 pm AEST.

NSB by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.